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Objective: To evaluate the outcomes of patients undergoing percutaneous placements of a biliary stent for obstructive
jaundice secondary to metastatic gastric cancer after gastrectomy.
Materials and Methods: Fifty patients (mean age, 62.4 years; range, 27-86 years) who underwent percutaneous placements
of a biliary stent for obstructive jaundice secondary to metastatic gastric cancer after gastrectomy were included. The
technical success rate, clinical success rate, complication rate, stent patency, patient survival and factors associated with
stent patency were being evaluated.
Results: The median interval between the gastrectomy and stent placement was 23.1 months (range, 3.9-94.6 months).
The 50 patients received a total of 65 stents without any major procedure-related complications. Technical success was
achieved in all patients. The mean total serum bilirubin level, which had been 7.19 mg/dL ± 6.8 before stent insertion,
decreased to 4.58 mg/dL ± 5.4 during the first week of follow-up (p < 0.001). Clinical success was achieved in 42 patients
(84%). Percutaneous transhepatic biliary drainage catheters were removed from 45 patients (90%). Infectious complications
were noted in two patients (4%), and stent malfunction occurred in seven patients (14%). The median stent patency was
233 ± 99 days, and the median patient survival was 179 ± 83 days. Total serum bilirubin level after stenting was an
independent factor for stent patency (p = 0.009).
Conclusion: Percutaneous transhepatic placement of a biliary stent for obstructive jaundice secondary to metastatic gastric
cancer after gastrectomy is a technically feasible and clinically effective palliative procedure.
Index terms: Biliary tract, malignant obstruction; Biliary tract, interventional procedures; Prosthesis, stent; Gastric carcinoma
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INTRODUCTION
Gastric cancer is the second leading cause of cancerrelated deaths in the world and the increasing incidence
of gastric cancers is being observed in association with
the increasing life-span of the general population (1).
Obstructive jaundice is an uncommon manifestation
of metastases from gastric cancer and its incidence is
reported to be 1.3-2.3% (2-4). Chemotherapy, surgical
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decompression, interventional decompression, and
radiation treatment are usually recommended with
palliative intent (5). Although the main treatment for
gastric cancer metastases is chemotherapy, jaundice is
one of the contraindications for chemotherapy, and the
prognosis for these patients is generally poor (6). Therefore,
biliary drainage is needed to relieve jaundice, prevent
complications, start chemotherapy and improve prognosis.
Percutaneous or endoscopic self-expandable metallic
stent insertion is a well-established method for palliating
a patient with an inoperative malignant biliary obstruction
due to hepatic, pancreatic, and gallbladder carcinoma and
metastatic lymphadenopathy (7-11). Although there have
been many studies on the outcomes after palliative stenting
for unresectable tumors, less is known about the outcomes
after stenting for obstructive jaundice secondary to gastric
cancer after resection. As endoscopic stenting is usually
difficult in patients with Billroth-II reconstruction or Rouxen-Y esopohagojejunostomy, the endoscopic approach is not
usually used in these patients. To our knowledge, there have
been few studies on the outcomes of percutaneous stents
placement for obstructive jaundice secondary to metastatic
gastric cancer and these studies included inoperable gastric
cancers (6, 12, 13). A large study is required to determine
the role of percutaneous stenting as a palliative treatment
in patients who were treated with gastrectomy. Therefore,
the purpose of this study is to evaluate the outcomes of
percutaneous stents placement for obstructive jaundice
secondary to metastatic gastric cancers after gastrectomy.

MATERIALS AND METHODS
Patient Population
We collected data from three referral hospitals. This
retrospective study was approved by the institutional
review boards of the three participating hospitals and the
requirement for individual patient consent was waived for
this study. We searched the patients who had percutaneous
stenting and gastrectomy from medical record or database.
Patients with obstructive jaundice secondary to afferent
loop syndromes or patients with extensive liver metastasis
causing liver failures were excluded. Patients whose primary
tumor was treated by endoscopy were also excluded.
From January 2003 to March 2010, 50 patients who had
obstructive jaundice secondary to metastatic gastric cancer
after gastrectomy underwent percutaneous placement
of a self-expandable metallic stent via a percutaneous
790

transhepatic biliary drainage (PTBD) tract. The patients
included 31 men and 19 women (mean age: 62.4 years, age
range: 27-86 years). All gastric tumors were histologically
confirmed as malignant advanced gastric cancers. All
diagnoses of cancer metastasis and obstructive jaundice
were based on clinical findings in addition to computed
tomography (CT), cholangiogram findings and serum
bilirubin levels (14, 15).
PTBD, Stent Placement and Follow-up
Percutaneous transhepatic biliary drainage procedures
were performed to treat obstructive jaundice and provide
access for the placement of a biliary stent. Broad spectrum
antibiotics were given intravenously 24 hours before each
PTBD procedure and for at least 48 hours afterwards (16).
Procedures were performed with the patient under local
anesthesia with 2% lidocaine hydrochloride and intravenous
conscious sedation. Under the guidance of ultrasonography
and fluoroscopy, unilateral PTBD was performed in 45
patients (right, n = 29; left, n = 16) and bilateral PTBD was
performed in 5 patients.
All placement of a biliary stent was performed 2-42 days
(mean, 14.35 days) after PTBD for decompressions of the
bile duct, improvements of cholangitis, and restorations
of liver function. Before placement of the biliary stents,
cholangiograms were obtained by injecting iodine contrast
media through a previously inserted PTBD catheter to
assess the decompression, stenosis site and exact anatomy
of the bile duct. After inserting the 0.035-inch guide
wire, the PTBD catheter was removed and a 5 Fr catheter
was advanced through the PTBD tract. The guide wire
and catheter were advanced across the stenosis to the
duodenum. The stenosis was opacified with injections of
contrast media through the catheter and the length was
measured. Balloon dilation of the stenosis before stent
placement was not routinely performed unless the stenosis
was tight. Balloon dilation was performed before stent
placement in five patients. The stent was placed to lie
across the stenosis. Stents were 3-4 cm longer than the
stricture to cover it completely including the proximal and
distal adjacent portions. Stent diameters ranged from 8 mm
to 10 mm and the average stent length was 6.6 cm (range:
4 to 10 cm).
Fifty patients received a total of 65 metallic stents. We
used various kinds of self-expanding metallic stents in this
study including Hercules DH biliary stents (S&G Biotech,
Seongnam, Korea) (n = 26), BONA stents (Standard Sci-Tech
Korean J Radiol 14(5), Sep/Oct 2013
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Inc., Seoul, Korea) (n = 19), Hanaro stents (MI Tech, Seoul,
Korea) (n = 8), Wallstents (Boston Scientific, Natick, MA,
USA) (n = 4), GD stents (TaeWoong Medical, Gimpo, Korea) (n
= 3), Sentinol stents (Boston Scientific) (n = 3), and Zilver
stents (Cook, Bloomington, IN, USA) (n = 2). The GD stent
is a partially covered stent and other stents are uncovered
stents.
Unilateral stenting was performed in forty patients (80%)
with the placement of one or two stents. In five patients,
separate stents were placed in the hepatic hilum to achieve
a Y-configuration. A T-configuration was achieved in five
patients using BONA stents with a mesh through technique
(17, 18). At the time of the initial stent placement, the
50 enrolled patients received a total of 62 stents. An
additional 3 stents were inserted to treat tumor ingrowths
in three patients.
After the stents placement, an 8.5 Fr drainage catheter
(Cook, Bloomington, IN or Sungwon medical, Cheongju,
Korea) was placed in the duct proximal to the stent and
cholangiograms were obtained to check the immediate
stent patency. After 2-3 days of waiting for spontaneous
stent expansions, follow-up cholangiograms were obtained.
Symptoms of biliary obstruction such as fever, pain, bile
leakage, and serum bilirubin level were also checked before
follow-up cholangiograms from medical records. If stent
function was appropriate with spontaneous passages of
contrast media to the duodenum, dilatation of the bile
ducts was improved on the follow-up cholangiogram
and there was no symptom of biliary obstruction, thus,
the drainage catheter was removed after PTBD catheter
clamping for one day. In cases with symptoms of biliary
obstruction, the PTBD drainage was maintained.
The patients were followed-up as outpatients during the
follow-up period. Serum bilirubin levels were checked to
determine whether biliary drainage was impeded. If patients
had obvious jaundice or a higher bilirubin level than before
stent placements, the stent was assumed to be obstructed.
In cases of recurrent jaundice or increased bilirubin levels,
patients were evaluated with CT. CT scans showed dilation
of the intrahepatic duct and the enhancement of inside the
stent which is interpreted as tissue growths (19). Stent
occlusion was diagnosed according to clinical, laboratory,
and radiologic findings. In the case of stent occlusion, we
performed decompressions of the bile duct by secondary
percutaneous interventional procedures depending on the
condition of the patients (20).

kjronline.org
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Definitions and Study Endpoints
Technical success was defined as placement of the stents
by providing continuous drainage of bile without any
major procedure-related complications. Clinical success
was defined as a > 30% decrease in the serum bilirubin
level relative to the baseline value (i.e., before stent
insertion) within the first week after stent insertions (21).
In cases where serum bilirubin level was normalized after
PTBD, clinical success was defined as maintenance of the
serum bilirubin level within the normal range after stent
placements.
Procedural complications were classified either as major
or minor according to the reporting standards of the Society
of Interventional Radiology (22). Major complications result
in admissions to a hospital for therapy, an unexpected
increase in the level of care, prolonged hospitalization,
permanent adverse sequelae, or death. Minor complications
resulting in no sequelae may require a short hospital stay
for observation.
Cholangitis was defined as recurrent episodes of
inexplicable fever. Stent patency was defined as the time
interval between initial stent placement and recurrence
of obstruction. At the time of death, a stent was assumed
to be patent if the patient had normal or only mildly
elevated serum bilirubin levels (< 3 mg/dL). If the
patients had obvious jaundice or higher serum bilirubin
levels as compared to before the stent placement at the
time of death, then the stent was assumed to have been
obstructed.
We evaluated the characteristics of primary gastric cancers
and malignant biliary obstructions. Also, we evaluated the
technical success rates, clinical success rates, complication
rates, stents patency and patient survivals. The serum
bilirubin levels before and during the follow-up period were
statistically analyzed using the Paired-sample t test with
PASW Statistics software (version 17.0; SPSS Inc., Chicago,
IL, USA). The stent patency and patient survival with 95%
confidence intervals (CIs) were calculated using the KaplanMeier survival (life-table) analysis. The following variables
were analyzed: gender, histology of previous gastrectomy,
serosal invasion, lymph node metastasis of primary gastric
cancer, hepatic metastasis after gastrectomy, level of biliary
stenosis, stent configuration, total serum bilirubin after
stenting, chemotherapy after stenting. We used univariate
log rank analysis and Cox’s proportional hazard model to
find significant variables.
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RESULTS
Thirty-five patients (70%) had undergone subtotal
gastrectomy and Billroth type II procedures while fifteen
patients (30%) underwent total gastrectomy and Roux-en Y
procedures. In 33 patients (66%), the primary carcinomas
were located either in the pylorus or in the antrum with or
without involvements of the stomach. In 17 patients (34%),
the primary carcinomas were located either in the body or
in the fundus (Table 1).
The mean interval from surgery to PTBD was 27.5 months
(range, 3.9-94.6 months). The mean total serum bilirubin
level before PTBD was 15.24 mg/dL. All patients had
node metastases. CT showed bile duct dilation and lymph
nodes in the hepatoduodenal ligament and retropancreatic
portion. Eleven patients (22%) had hepatic metastasis.
Stenoses were diagnosed on CT and cholangiogram after
PTBD and before biliary stent placement. Main level of
stenoses were located at the common hepatic duct in 23
patients (46%), proximal common bile duct in 16 patients
(32%) and the distal common bile duct in 11 patients (22%)
on cholangiogram. Among 23 patients who had stenosis in
the common hepatic duct, 10 patients also had stenosis at
the hilum (Table 2).
Technical success was achieved in all 50 patients. The
mean total serum bilirubin level, which was 7.19 mg/dL
± 6.8 before stent insertion, decreased to 4.58 mg/dL ±
5.4 during the first week of follow-up, and this difference
was statistically significant (p < 0.001). Clinical success
was achieved in 42 of 50 patients (84%). Among the eight
patients, who didn’t achieve clinical success, total serum
bilirubin was increased after stent insertions in 5 patients
and total serum bilirubin was mild decreased in 3 patients.
In thirty patients (60%), total serum bilirubin level
decreased ≤ 2 mg/dL after stenting. Forty-five patients
(90%) showed a decrease in total serum bilirubin levels
within the first week after stent placement. The PTBD
catheter could be removed in these 45 patients because the
stents were patented on cholangiogram acquired 2-3 day
after stent insertions and there were no symptoms of biliary
obstruction (Fig. 1). One patient wanted the drain catheter
to be removed despite clinical failures and died 30 days
later due to disease progressions. In other four patients, the
PTBD catheter could not be removed due to clinical failures.
PTBD catheter was kept and changed to prevent cholangitis.
Among forty-two patients who achieved clinical successes,
twenty-two patients (53%) were treated by chemotherapy
792

Table 1. Characteristics of Primary Gastric Cancer
Variable
Location of primary tumor
Upper 1/2
Lower 1/2
Macroscopic type
Borrmann type 1
Borrmann type 2
Borrmann type 3
Borrmann type 4
Histologic type
Differentiated
Signet ring cell
Serosal invasion
No
Yes
Lymph node metastasis
No
Yes
Previous gastrectomy
Total gastrectomy
Subtotal gastrectomy

n

%

17
33

34
66

2
7
36
5

4
14
72
10

45
5

90
10

20
30

40
60

4
46

8
92

15
35

30
70

Table 2. Characteristics of Malignant Biliary Obstruction
Variables
Main level of obstruction
Common hepatic duct, hilum
Proximal common bile duct
Distal common bile duct
Hepatic metastasis

n

%

23
16
11
11

46
32
22
22

after stent insertions. Other twenty patients didn’t receive
chemotherapy due to disease progressions, poor conditions
or denials for further treatment. Forty-seven patients (94%)
were discharged from hospital after stent placement. Three
patients died during hospitalization (mean: 18 days, range:
3-32 days): two died due to disease progressions, and one
secondary to pneumonia.
There were no major procedure-related complications.
In one patient who underwent a subtotal gastrectomy and
Billroth type II procedure, a sludge material was noted in
the CBD on the follow-up cholangiogram; however, this
patient was managed conservatively and the catheter was
being removed. Complications were noted in nine patients
(18%) during the follow-up period. Infectious complications
including cholecystitis and hepatic abscess was noted in
two patients (4%) (mean: 151 days, range: 38-264 days),
who were treated with percutaneous cholecystostomy and
percutaneous hepatic abscess drainage. Two hundred sixtyKorean J Radiol 14(5), Sep/Oct 2013
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A

B

C

Fig. 1. Sixty four-year-old female with obstructive jaundice resulting from gastric cancer after gastrectomy.

A. Cholangiogram via left PTBD tract shows severe stricture at distal common bile duct. B. Guide wire was passed into duodenum and partially
covered stent was inserted into common bile duct. C. Cholaniogram obtained three days after stent placement demonstrating further expansion
of stent and good passage of contrast media. PTBD = percutaneous transhepatic biliary drainage
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Fig. 2. Kaplan-Meier analysis of stent patency and patient survival.

A. Kaplan-Meier analysis of primary stent patency. Median stent patency time was 233 ± 99 days (95% CI, 38-427 days). B. Kaplan-Meier analysis
of patient survival. Median patient survival time was 179 ± 83 days (95% CI, 16-342 days). CI = confidence interval

four days after the stent placements, about 3 cm sized, left
lateral segmental hepatic abscess developed in one patient
who placed the stent through right PTBD tract. Recurrent
jaundice was noted in seven patients (14%) after a mean of
243.9 days (range: 56-635 days); all showed increased total
serum bilirubin levels, intrahepatic ductal dilation, and
enhancements inside the stent on CT scans. These seven
patients were treated by PTBD, and second biliary stent was
placed in three patients.
kjronline.org
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The median and mean overall stent patency period was
233 ± 99 days (95% CI, 38-427 days) and 286 ± 49 days
(95% CI, 190-382 days), respectively. Univariate log rank
analysis showed that total serum bilirubin level after
stenting (p < 0.001) and chemotherapy after stenting (p
= 0.002) were significantly associated with stent patency.
Multiple Cox’s proportional hazard regression analysis
showed total serum bilirubin level after stenting (p =
0.009) was independent predictor of stent patency. Median
793
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Fig. 3. Multiple Cox’s regression analysis of stent patency.
Kaplan-Meier curves showing stent patency according to total serum
bilirubin after stenting.

stent patency period was significantly longer in patients
with total serum bilirubin level ≤ 2 mg/dL (309 days; 95%
CI, 119-498 days) compared to in > 2 mg/dL (59 days;
95% CI, 43-75 days) after stenting. During the follow-up
period, 25 patients died 3-710 days after stent placements.
Among these 25 patients, 12 patients had normal or mildly
elevated serum bilirubin levels (< 3 mg/dL). The median
and mean of overall patient survival period was 179 ± 83
days (95% CI, 16-342 days) and 274 ± 47 days (95% CI,
181-367 days), respectively (Figs. 2, 3).

DISCUSSION
Although malignant biliary obstruction is an uncommon
complication of gastric cancer, metastatic gastric cancer
is the most frequent cause of metastatic obstructive
jaundice (50%), followed by colon cancer (20%), breast
cancer and melanoma (6, 23). Metastatic lymphadenopathy
along the hepatoduodenal ligament is one of the main
causes of biliary obstruction of gastric cancer, and its
most common site is around the cystic duct. Standard D2
lymph node dissection does not remove lymph nodes along
the hepatoduodenal ligament. Two-thirds of such node
metastases causing malignant biliary obstructions derived
from gastric cancer in the antrum are located closely to
the hepatoduodenal ligament. Direct invasion of recurrent
gastric cancer also causes obstructive jaundice. During
794

balloon dilation or stent insertion, eccentric smooth round
or oval-shaped defects on the right lateral wall of the bile
duct were commonly noted and this finding was due to
extrinsic compressions from enlarged lymph nodes (15). In
our study, 66% of patients had gastric cancer located in the
lower 1/2 of the stomach, while bile duct stenoses were
located at the common hepatic duct and proximal common
bile duct in 78% of patients.
The surgical approach to malignant biliary obstruction is
less applicable to biliary obstruction caused by metastatic
tumors to the porta hepatis with extrinsic obstruction.
Palliative bypass can prolong patient survival if properly
performed. Two studies have shown that surgical treatment
is associated with higher postoperative mortality, morbidity
and a longer hospital stay than non-surgical drainages
(24, 25). Endoscopic retrograde cholangiography (ERCP)
is usually difficult in these patients because of a distorted
bowel loop due to the Billroth II reconstruction or Rouxen-Y esophagojejunostomy (26, 27). Afferent loop
perforation is a specific complication of ERCP in these
patients and these patients have a mortality rate varying
from 0.7-5% (27). Therefore, we use PTBD as an initial
treatment for patients with malignant biliary obstruction
caused by metastatic gastric cancers. Although PTBD is
expected to improve obstructive jaundice and drain the
infected bile, it could also be associated with catheterrelated complications and lead to a deteriorating quality
of life due to difficulties maintaining an external catheter
and the need for regular catheter changes. Frequently
encountered complications of PTBD are catheter
dislodgement, cholangitis, and bile leakage (3, 28). Selfexpandable metallic stents provide more comfort than PTBD.
Although there have been many studies of percutaneous
stent placement for malignant biliary obstruction, studies of
stent placement for obstructive jaundice caused by gastric
cancer after limited gastrectomy (6, 12).
The clinical success in our study is comparable to that in
previous studies that focused on PTBD efficacy for palliative
treatment (4, 12). Migita et al. (12) reported significant
serum bilirubin decreases in 76% of the patients after
PTBD. After the intervention, performance status improved
in 68% of patients; however, 45% of patients could not
be discharged from the hospital after the intervention for
progressions of the underlying malignancy or jaundice. In
our study, 90% of PTBD catheters could be removed and
94% of our patients were discharged from the hospital after
stent insertions. These results reveal that percutaneous
Korean J Radiol 14(5), Sep/Oct 2013
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stent placement for obstructive jaundice resulting from
gastric cancer after gastrectomy is an effective palliative
treatment. Gwon et al. (13) reported their experience of
palliative treatment in 117 patients with malignant biliary
obstruction caused by metastatic gastric cancer. In patients
who had previously undergone gastrectomy for primary
gastric cancer, the median interval between previous
gastrectomy and onset of biliary obstruction was 26 months.
Clinical success was 91% of 54 patients who underwent
stent placements. Median stent patency time was 351 days.
Among 54 patients who underwent stenting, there were
patients who did not undergo gastrectomy. They didn’t
find significant factors associated with stent patency. Our
study only included patients who underwent gastrectomy.
Percutaneous stenting was an effective palliative treatment
and total serum bilirubin level after stenting was an
independent predictor of stent patency.
The purpose of percutaneous stenting for the treatment
of obstructive jaundice is not only to improve jaundice,
but also to give the patients an opportunity to receive
palliative treatments such as systemic chemotherapy. Many
systemic chemotherapy drugs require intact mechanisms of
bile excretion to prevent toxicity. Twenty-two of the fifty
patients (44%) who had a significant decrease in serum
bilirubin level after stent placement received chemotherapy.
Previous studies suggested that the use of chemotherapy
after PTBD or stenting might prolong the survival of
patients with obstructive jaundices caused by the local
recurrence of gastric cancers (4, 12, 13).
There were no major procedure-related complications
in our study. During the follow-up period, complications
were noted in nine patients (18%). Cholecystitis and
hepatic abscess were noted in two patients (4%). Recurrent
jaundices and stent malfunctions were noted in seven
patients (14%). These seven patients were treated by PTBD
and a second biliary stent was placed in three patients.
Previous studies reported that 7-30% of patients who
underwent biliary stenting for palliation had complications
and 14-25% of patients had recurrent symptoms of jaundice
during the follow-up periods (29-31). Our results are
comparable to those described in the studies.
The stent patency and patient survival period in our
study were better than those of previous studies on
cholangiocarcinoma, gallbladder carcinoma, and pancreatic
carcinoma (32, 33). However, making comparisons to
previous studies is difficult because patients were treated
at a different stage, and each tumor had a different
kjronline.org
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histological type and biological behavior. Yet, the response
to chemotherapy in our patients may have improved the
survival period. Thirty-nine patients (78%) had stenoses
at the common hepatic duct and proximal common bile
duct mainly due to extrinsic compressions by malignant
lymphadenopathy. These extrinsic compressive lesions may
have responded better to biliary stent placements, and
thus, may have improved stent patency. A larger study is
needed to identify independent factors associated with
stent patency and patient survival rates.
There are several limitations to our study. First, this
was a retrospective study. Second, this was a multicenter
study with unconvered or partially covered types of stents
used, which may have influenced stent patency. Third,
gastric cancer recurrence was not confirmed histologically
because reoperation or endoscopic biopsy for nodes in
the hepatoduodenal ligament portion was very difficult.
Jaundice was diagnosed during follow-up after gastrectomy
due to the cancer, and mean interval from surgery to PTBD
was 27.5 months. Imaging findings, clinical symptoms and
laboratory findings were compatible with gastric cancer
metastasis.
In conclusion, percutaneous transhepatic placement of a
biliary stent for obstructive jaundice caused by metastatic
gastric cancer after a gastrectomy is a technically feasible,
safe, and clinically effective palliative procedure. Total
serum bilirubin level after stenting was an independent
factor for stent patency.
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